The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use ... combined with promising results from ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use ... combined with promising results from the first-in-human ‘SIGHT-I’ trial in China, underscored its potential to ...

Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2024 Huntington Study ...

The first trial of that approach was conducted in China in 2016 and involved a cell-based therapy for lung cancer, and other studies have followed, including a study of CRISPR Therapeutics and ...

Editas Medicine (NASDAQ:EDIT – Get Free Report) had its target price decreased by equities research analysts at Wells Fargo & Company from $9.00 to $7.00 in a report issued on Tuesday, Benzinga ...

A new report from leading CRO Novotech has shed light on the current state of play in the global cervical cancer clinical ...

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

BEIJING, Nov 6 (Reuters) - China's Premier Li Qiang expressed Beijing's support for Myanmar's political reconciliation and transition efforts in a meeting with Myanmar's junta leader on Wednesday ...